CTLA4 and B-cell non-Hodgkin lymphoma: In human medicine, several clinical trials using ipilimumab, which blocks the CTLA-4 signal or CTLA-4 inhibitors, have been widely reported and offered prolonged survival with manageable side effects in patients with B-cell lymphoma [69, 70].